Почетна › Кронова болест › Džordžija
Kliničke studije za Кронова болест u državi Džordžija
20 studija za Кронова болест traži učesnike na lokacijama u državi Džordžija.
Gradovi u državi Džordžija
Zvanični tekst studije (na engleskom)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Morehouse School Of Medicine ( Site 5071), Atlanta
- Gastroenterology Associates of Central Georgia ( Site 5048), Macon
Тражи се учесникФаза 3
Узраст од 16 до 80 · Оба пола · Ажурирано 10. 11. 2026. · NCT06430801A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Atlanta Gastroenterology Associates - Peachtree Dunwoody, Atlanta
Тражи се учесникФаза 2
Узраст од 18 до 80 · Оба пола · Ажурирано 4. 11. 2026. · NCT07483073A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Atlanta Gastroenterology Specialists, PC, Atlanta
- Atlanta Gastroenterology Associates (Part of United Digestive), Atlanta
Тражи се учесникФаза 2
Узраст од 18 до 85 · Оба пола · Ажурирано 4. 11. 2026. · NCT06226883A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- Atlanta Gastroenterology Associates - Peachtree Dunwoody, Atlanta
Тражи се учесникФаза 2
Узраст од 18 до 80 · Оба пола · Ажурирано 4. 11. 2026. · NCT07483099A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Emory University, Atlanta
- Atlanta Gastroenterology Associates, Atlanta
- Children's Center for Digestive Health Care, Atlanta
- и још 1
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07196722A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Atlanta Gastroenterology Specialists, Suwanee
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07577843A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Emory University, Atlanta
- Children's Center for Digestive Healthcare, Atlanta
Тражи се учесникФаза 3
Узраст 3 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06663332A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Emory University, Atlanta
- Children's Center for Digestive Health Care, Atlanta
Тражи се учесникФаза 3
Узраст од 2 до 17 · Оба пола · Ажурирано 3. 11. 2026. · NCT05923073A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Morehouse School of Medicine, Atlanta
- Gastroenterology Associates of Central GA, Macon
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07499232A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Emory University Hospital, The Emory Clinic, Atlanta
- Atlanta Center For Gastroenterology, P.C., Decatur
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 2. 11. 2026. · NCT06233461A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
- Investigational Site Number: 8400019, Marietta
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 2. 11. 2026. · NCT06958536A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Digestive Healthcare of Georgia, Atlanta
- AGA GA Research LLC, Atlanta
Тражи се учесникФаза 4
Узраст од 18 до 80 · Оба пола · Ажурирано 28. 10. 2026. · NCT06581328Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Associates of Central Georgia /ID# 280464, Macon
- Gastroenterology Consultants - Roswell /ID# 281235, Roswell
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 27. 10. 2026. · NCT07697456An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Atlanta Gastroenterology Associates-Site Number: 8400109, Atlanta
- M3 Wake Research - Atlanta-Site Number: 8400028, Sandy Springs
- EBGS Clinical Research Center, LLC-Site Number: 8400037, Snellville
- и још 1
Тражи се учесникФаза 3
Узраст од 16 до 80 · Оба пола · Ажурирано 21. 10. 2026. · NCT07184931A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Emory University School of Medicine, Atlanta
- Children's Center for Digestive Health Care, LLC, Atlanta
Тражи се учесникФаза 3
Узраст од 2 до 19 · Оба пола · Ажурирано 7. 10. 2026. · NCT04844606A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Emory University, Atlanta
- Children's Center for Digestive Health Care, LLC, Atlanta
Тражи се учесникФаза 3
Узраст од 2 до 17 · Оба пола · Ажурирано 7. 10. 2026. · NCT05509777Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Gastroenterology Associates of Central Georgia /ID# 265547, Macon
Тражи се учесникФаза 2
Узраст од 18 до 75 · Оба пола · Ажурирано 25. 9. 2026. · NCT06548542A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Childrens Center For Digestive Healthcare, Atlanta
Тражи се учесникФаза 3
Узраст 2 и старији · Оба пола · Ажурирано 7. 5. 2026. · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Childrens Center For Digestive Healthcare, Atlanta
Тражи се учесникФаза 3
Узраст од 2 до 17 · Оба пола · Ажурирано 5. 5. 2026. · NCT04779320A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Atlanta
- Mirador Therapeutics Selected Site, Snellville
Тражи се учесникФаза 2
Узраст од 18 до 80 · Оба пола · Ажурирано 12. 3. 2026. · NCT07113522Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.